{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:42:05Z","timestamp":1794930125412,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clear-cell renal cell carcinoma (ccRCC) is a common therapy resistant disease with aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are treated with targeted therapies based on clinical features: low-risk patients are usually treated with anti-angiogenic drugs and intermediate\/high-risk patients with immune therapy. However, there are no biomarkers available to guide treatment choice for these patients. A recently published phase II clinical trial observed a correlation between ccRCC patients\u2019 clustering and their response to targeted therapy. However, the clustering of these groups was not distinct. Here, we analyzed the gene expression profile of 469 ccRCC patients, using featured selection technique, and have developed a refined 66-gene signature for improved sub-classification of patients. Moreover, we have identified a novel comprehensive expression profile to distinguish between migratory stromal and immune cells. Furthermore, the proposed 66-gene signature was validated using a different cohort of 64 ccRCC patients. These findings are foundational for the development of reliable biomarkers that may guide treatment decision-making and improve therapy response in ccRCC patients.<\/jats:p>","DOI":"10.1038\/s41598-020-58804-y","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T11:04:48Z","timestamp":1580987088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-4673","authenticated-orcid":false,"given":"Ninadh M.","family":"D\u2019Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1413","authenticated-orcid":false,"given":"Raunak","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-8875","authenticated-orcid":false,"given":"Cesar U.","family":"Monjaras-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Hach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia I.","family":"Chavez-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan I.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"58804_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4161\/cbt.10.7.13247","volume":"10","author":"G Banumathy","year":"2010","unstructured":"Banumathy, G. & Cairns, P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther. 10, 658\u2013664, https:\/\/doi.org\/10.4161\/cbt.10.7.13247 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"58804_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749\u2013757, https:\/\/doi.org\/10.1038\/s41591-018-0053-3 (2018).","journal-title":"Nat. Med."},{"key":"58804_CR3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.Ccr-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757\u20131761, https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-2599 (2007).","journal-title":"Clin. Cancer Res."},{"key":"58804_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Sci. 359, 801\u2013806, https:\/\/doi.org\/10.1126\/science.aan5951 (2018).","journal-title":"Sci."},{"key":"58804_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. reviews. Cancer 19, 133\u2013150, https:\/\/doi.org\/10.1038\/s41568-019-0116-x (2019).","journal-title":"Nat. reviews. Cancer"},{"key":"58804_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N. Engl. J. Med. 378, 2093\u20132104, https:\/\/doi.org\/10.1056\/NEJMoa1801946 (2018).","journal-title":"N. Engl. J. Med."},{"key":"58804_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021, https:\/\/doi.org\/10.1016\/S1470-2045(17)30516-8 (2017).","journal-title":"Lancet Oncol."},{"key":"58804_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3322\/caac.21411","volume":"67","author":"PC Barata","year":"2017","unstructured":"Barata, P. C. & Rini, B. I. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J. Clin. 67, 507\u2013524, https:\/\/doi.org\/10.3322\/caac.21411 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"58804_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","volume":"16","author":"JJ Ko","year":"2015","unstructured":"Ko, J. J. et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 16, 293\u2013300, https:\/\/doi.org\/10.1016\/S1470-2045(14)71222-7 (2015).","journal-title":"Lancet Oncol."},{"key":"58804_CR10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1097\/01.ju.0000035885.91935.d5","volume":"168","author":"I Frank","year":"2002","unstructured":"Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395\u20132400, https:\/\/doi.org\/10.1097\/01.ju.0000035885.91935.d5 (2002).","journal-title":"J. Urol."},{"key":"58804_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 378, 1277\u20131290, https:\/\/doi.org\/10.1056\/NEJMoa1712126 (2018).","journal-title":"N. Engl. J. Med."},{"key":"58804_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.eururo.2014.02.035","volume":"66","author":"SA Brooks","year":"2014","unstructured":"Brooks, S. A. et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77\u201384, https:\/\/doi.org\/10.1016\/j.eururo.2014.02.035 (2014).","journal-title":"Eur. Urol."},{"key":"58804_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.eururo.2018.07.032","volume":"74","author":"L Qu","year":"2018","unstructured":"Qu, L. et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur. Urol. 74, 756\u2013763, https:\/\/doi.org\/10.1016\/j.eururo.2018.07.032 (2018).","journal-title":"Eur. Urol."},{"key":"58804_CR14","doi-asserted-by":"publisher","first-page":"e0131278","DOI":"10.1371\/journal.pone.0131278","volume":"10","author":"JL Xu","year":"2015","unstructured":"Xu, J. L. et al. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One 10, e0131278, https:\/\/doi.org\/10.1371\/journal.pone.0131278 (2015).","journal-title":"PLoS One"},{"key":"58804_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","volume":"9","author":"AA Hakimi","year":"2019","unstructured":"Hakimi, A. A. et al. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discov. 9, 510\u2013525, https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0957 (2019).","journal-title":"Cancer Discov."},{"key":"58804_CR16","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 17009, https:\/\/doi.org\/10.1038\/nrdp.2017.9 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"58804_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research, N.","year":"2013","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nat. 499, 43\u201349, https:\/\/doi.org\/10.1038\/nature12222 (2013).","journal-title":"Nat."},{"key":"58804_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bbamem.2013.07.009","volume":"1838","author":"N Joseph","year":"2014","unstructured":"Joseph, N., Reicher, B. & Barda-Saad, M. The calcium feedback loop and T cell activation: how cytoskeleton networks control intracellular calcium flux. Biochim. Biophys. Acta 1838, 557\u2013568, https:\/\/doi.org\/10.1016\/j.bbamem.2013.07.009 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"58804_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10994-006-6226-1","volume":"63","author":"P Geurts","year":"2006","unstructured":"Geurts, P., Ernst, D. & Wehenkel, L. Extremely randomized trees. Mach. Learn. 63, 3\u201342, https:\/\/doi.org\/10.1007\/s10994-006-6226-1 (2006).","journal-title":"Mach. Learn."},{"key":"58804_CR20","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.2147\/CMAR.S185270","volume":"10","author":"W Xiao","year":"2018","unstructured":"Xiao, W., Wang, X., Wang, T. & Xing, J. TRIM2 downregulation in clear cell renal cell carcinoma affects cell proliferation, migration, and invasion and predicts poor patients\u2019 survival. Cancer Manag. Res. 10, 5951\u20135964, https:\/\/doi.org\/10.2147\/CMAR.S185270 (2018).","journal-title":"Cancer Manag. Res."},{"key":"58804_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fimmu.2019.00333","volume":"10","author":"AE Vilgelm","year":"2019","unstructured":"Vilgelm, A. E. & Richmond, A. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Front. Immunol. 10, 333, https:\/\/doi.org\/10.3389\/fimmu.2019.00333 (2019).","journal-title":"Front. Immunol."},{"key":"58804_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/ni1275","volume":"6","author":"AD Luster","year":"2005","unstructured":"Luster, A. D., Alon, R. & von Andrian, U. H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6, 1182\u20131190, https:\/\/doi.org\/10.1038\/ni1275 (2005).","journal-title":"Nat. Immunol."},{"key":"58804_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","volume":"124","author":"J Condeelis","year":"2006","unstructured":"Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263\u2013266, https:\/\/doi.org\/10.1016\/j.cell.2006.01.007 (2006).","journal-title":"Cell"},{"key":"58804_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Random forests. Mach. Learn. 45, 5\u201332, https:\/\/doi.org\/10.1023\/A:1010933404324 (2001).","journal-title":"Mach. Learn."},{"key":"58804_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/B:AMAI.0000018580.96245.c6","volume":"41","author":"LE Raileanu","year":"2004","unstructured":"Raileanu, L. E. & Stoffel, K. Theoretical comparison between the Gini Index and Information Gain criteria. Ann. Math. Artif. Intel. 41, 77\u201393, https:\/\/doi.org\/10.1023\/B:AMAI.0000018580.96245.c6 (2004).","journal-title":"Ann. Math. Artif. Intel."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58804-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T15:06:46Z","timestamp":1672672006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58804-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["58804"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-58804-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2026"}}